Emerging antiretroviral drug interactions.
With HIV-infected patients living longer and recommendations to initiate antiretrovirals (ARVs) being made earlier, the likelihood for potential drug-drug interactions between ARVs and concurrent medications used to manage co-morbid conditions will increase. In order to maximize the clinical benefit and minimize potential toxicity of ARVs and co-administered medications, it is important for clinicians to recognize significant drug-drug interactions. This article highlights clinically significant drug-drug interactions with antituberculosis agents, antimalarials, anticoagulants, chemotherapeutic agents and pulmonary antihypertensive agents when they are co-administered with newer ARVs (e.g. darunavir, raltegravir, maraviroc and etravirine).
Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA. vpham@jhmi.edu
Paul A
PA
Pham
Charles
C
Flexner
D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans
D044966:Anti-Retroviral Agents